Literature DB >> 207783

Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients.

R B Pollard, K H Rand, A M Arvin, T C Merigan.   

Abstract

Two assays of cell-mediated immunity, lymphocyte transformation and interferon production, were adapted to test for specific immunity to cytomegalovirus (CMV). Normal individuals seropositive for CMV had a mean transformation index of 7.9 in response to antigen of the Davis strain of CMV, whereas all of 14 seronegative normal individuals had transformation indexes of less than or equal to 3.0. Interferon production in seropositive and seronegative individuals was not statistically different. One to two months after CMV mononucleosis (after the termination of viruria), normal individuals had increased transformation indexes. Recipients of cardiac transplants within six months after transplant had normal levels of antibody to CMV; lymphocyte transformation and interferon production in these subjects were markedly decreased and returned to normal by three years and between one and three years after transplant, respectively. A syndrome of unexplained fever, hepatitis, pneumonitis, leukopenia, and atypical lymphocytes was common in a group of recipients with primary CMV infection. Shedding of virus was frequent in these symptomatic patients and in patients with repeat infection during the first three years after transplant. These assays appear to identify periods of immune deficits correlating with increased incidence of infection with CMV.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207783     DOI: 10.1093/infdis/137.5.541

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals.

Authors:  Elizabeth Sinclair; Douglas Black; C Lorrie Epling; Alexander Carvidi; Steven Z Josefowicz; Barry M Bredt; Mark A Jacobson
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

2.  Cell-mediated immunity to cytomegalovirus in immunocompromised patients: effect of radiation or chemotherapy.

Authors:  Y Agatsuma; P Fitzpatrick; A Kaul; R Kaul; R Kohli; A V Paves; P L Ogra
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

3.  Cellular immune response to cytomegalovirus infection after renal transplantation.

Authors:  C C Linnemann; C A Kauffman; M R First; G M Schiff; J P Phair
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

Review 4.  Heart transplantation: approaching a new century.

Authors:  B Radovancević; O H Frazier
Journal:  Tex Heart Inst J       Date:  1999

Review 5.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

6.  Mitogenic activity in human embryonic fibroblasts early after infection by human cytomegalovirus.

Authors:  N Takehara; K Ryoke; T Kurimura
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

7.  In vitro stimulation of lymphocytes by different strains of cytomegalovirus.

Authors:  L Gärtner; J A Wilhelm; R Czieschnek
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

8.  Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses.

Authors:  B Hafkin; R B Pollard; M L Tiku; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Cell-mediated and humoral immunity to herpesviruses during and after herpes zoster infections.

Authors:  O S Sørensen; S Haahr; A Møller-Larsen; K Wildenhoff
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Lymphocyte blastogenesis and interferon production in adult human leukocyte cultures stimulated with cytomegalovirus antigens.

Authors:  S E Starr; B Dalton; T Garrabrant; K Paucker; S A Plotkin
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.